Abrocitinib Therapeutic Cheat Sheet
Abrocitinib is an oral, once-daily selective Janus kinase 1 (JAK1) inhibitor approved for moderate-to-severe atopic dermatitis. It can provide rapid improvement in pruritus and skin disease and is a useful treatment option for many patients. As an oral medication, it may also be preferred by patients who want to avoid injections. When prescribing abrocitinib, it is important to discuss laboratory …
Abrocitinib is an oral, once-daily selective Janus kinase 1 (JAK1) inhibitor approved for moderate-to-severe atopic dermatitis. It can provide rapid improvement in pruritus and skin disease and is a useful treatment option for many patients. As an oral medication, it may also be preferred by patients who want to avoid injections. When prescribing abrocitinib, it is important to discuss laboratory … 
Emily Murphy, MD, FAAD, is committed to improving care for vulvar dermatoses, which is why she founded the Vulvar Health Program at the George Washington University School of Medicine & Health Sciences. In this Next Steps in Derm interview, in partnership with the ODAC Dermatology Conference, Dr. Murphy shares what her clinical experience has taught her about diagnosing and managing vulvar der … 
Surgery is the gold standard for skin cancer treatment, but sometimes surgery isn’t the best option. Perhaps the patient isn’t healthy enough or the patient simply refuses to go under the knife. Topical therapy is an alternative, but patient compliance is a concern. Enter fractional laser-assisted drug delivery (LADD): a non-surgical approach that enhances penetration of topical treatments, le … 
Ronda S. Farah, MD, FAAD, knows the impact of hair and scalp disorders on patients’ quality of life. Dr. Farah is an associate of professor of dermatology at the University of Minnesota and founder of Alluma Dermatology. For Dr. Farah, quality care begins with a thorough hair and scalp exam. In this Next Steps in Derm video interview, conducted in partnership with the ODAC Dermatology Conference … 
Scarring alopecias in skin of color are increasingly recognized and remain a major cause of irreversible hair loss. During the 2025 Skin of Color Update in New York City, Susan C. Taylor, MD, presented an updated clinical approach to identifying and managing lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), and central centrifugal cicatricial alopecia (CCCA) with a focus on early detect …